Exelixis, Inc. (EXEL) on Decifer

Decifer ranks EXEL number 4 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 30% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is expected to grow about 13% a year, profits grew 60% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• As one of five credible suppliers of approved specialty drug franchises with returns near 30%, profits up 60% and widening margins on a green watchboard, it is only partly recognized and helped by momentum of 20 out of 35.

The current read

The evidence on EXEL lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Exelixis, Inc. operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Read the full EXEL research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.